<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24454288</article-id><article-id pub-id-type="pmc">3887272</article-id><article-id pub-id-type="doi">10.3389/fphar.2013.00175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Population-based colorectal cancer screening: comparison of two fecal occult blood test</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zubero</surname><given-names>Miren B.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arana-Arri</surname><given-names>Eunate</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pijoan</surname><given-names>Jos&#x000e9; I.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Portillo</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Idigoras</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Urrutia</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Samper</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uranga</surname><given-names>Bego&#x000f1;a</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bujanda</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Clinical Epidemiology Unit, Cruces University Hospital, Basque Health Service</institution><country>Barakaldo, Bizkaia, Spain</country></aff><aff id="aff2"><sup>2</sup><institution>BioCruces Health Research Institute</institution><country>Bizkaia, Spain</country></aff><aff id="aff3"><sup>3</sup><institution>Biomedical Research Center Network for Epidemiology and Public Health</institution><country>Bizkaia, Spain</country></aff><aff id="aff4"><sup>4</sup><institution>Colorectal Cancer Screening Programme Coordinating Centre, Basque Health Service</institution><country>Bizkaia, Spain</country></aff><aff id="aff5"><sup>5</sup><institution>Clinical Biochemistry Service, Cruces University Hospital, Basque Health Service</institution><country>Barakaldo, Bizkaia, Spain</country></aff><aff id="aff6"><sup>6</sup><institution>Clinical Biochemistry Service, Donostia University Hospital, Basque Health Service</institution><country>Donostia, Gipuzkoa, Spain</country></aff><aff id="aff7"><sup>7</sup><institution>Digestive Department, Donostia University Hospital, Basque Health Service</institution><country>Donostia, Gipuzkoa, Spain</country></aff><aff id="aff8"><sup>8</sup><institution>Clinical Biochemistry Service, Araba University Hospital, Basque Health Service</institution><country>Gasteiz, Araba, Spain</country></aff><aff id="aff9"><sup>9</sup><institution>Biodonostia Research Institute</institution><country>Donostia, Spain</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: <italic>Dominique J. Dubois, Universit&#x000e9; Libre de Bruxelles, Belgium</italic></p></fn><fn fn-type="edited-by"><p>Reviewed by: <italic>Brian Godman, Karolinska Institutet, Sweden; Marianne Klemp, Norwegian Knowledge Center for the Health Services, Norway</italic></p></fn><corresp id="fn001">*Correspondence: <italic>Eunate Arana-Arri, Clinical Epidemiology Unit, Cruces University Hospital, Basque Health Service, Plaza de Cruces 12, 48903 Barakaldo, Bizkaia, Spain e-mail: <email xlink:type="simple">eunate.aranaarri@osakidetza.net</email></italic></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2013</year></pub-date><volume>4</volume><elocation-id>175</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Zubero, Arana-Arri, Pijoan, Portillo, Idigoras, L&#x000f3;pez-Urrutia, Samper, Uranga, Rodr&#x000ed;guez and Bujanda.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><bold>Background:</bold> The aim of screening for colorectal cancer is to improve prognosis by the detection of cancer at its early stages. In order to inform the decision on the specific test to be used in the population-based program in the Basque Autonomous Region (Spain), we compared two immunochemical fecal occult blood quantitative tests (I-FOBT).</p><p><bold>Methods:</bold> Residents of selected study areas, aged 50&#x02013;69 years, were invited to participate in the screening. Two tests based on latex agglutination (OC-Sensor and FOB Gold) were randomly assigned to different study areas. A colonoscopy was offered to patients with a positive test result. The cut-off point used to classify a result as positive, according to manufacturer&#x02019;s recommendations, was 100 ng/ml for both tests.</p><p><bold>Results:</bold> The invited population included 37,999 individuals. Participation rates were 61.8% (<italic>n</italic> = 11,162) for OC-Sensor and 59.1% (<italic>n</italic> = 11,786) for FOB Gold (<italic>p</italic> = 0.008). Positive rate for OC-Sensor was 6.6% (<italic>n</italic> = 737) and 8.5% (<italic>n</italic> = 1,002) for FOB Gold (<italic>p</italic> &#x0003c; 0.0001). Error rates were higher for FOB gold (2.3%) than for OC-Sensor (0.2%; <italic>p</italic> &#x0003c; 0.0001). Predictive positive value (PPV) for total malignant and premalignant lesions was 62.4% for OC-Sensor and 58.9% for FOB Gold (<italic>p</italic> = 0.137), respectively.</p><p><bold>Conclusion:</bold> OC-Sensor test appears to be superior for I-FOBT-based colorectal cancer screening, given its acceptance, ease of use, associated small number of errors and its screening accuracy. FOB Gold on the other hand, has higher rate of positive values, with more colonoscopies performed, it shows higher detection incidence rates, but involves more false positives.</p></abstract><kwd-group><kwd>immunochemical fecal occult blood test</kwd><kwd>population screening</kwd><kwd>health outcomes research</kwd><kwd>health impact assessment</kwd><kwd>colorectal cancer</kwd></kwd-group><counts><fig-count count="0"/><table-count count="5"/><equation-count count="0"/><ref-count count="39"/><page-count count="8"/><word-count count="0"/></counts></article-meta></front><body><sec><title>INTRODUCTION</title><p>Colorectal cancer (CRC) is the third leading cancer and the fourth leading cause of cancer deaths worldwide, with 1.2 million estimated new cases and 609,000 estimated deaths in 2008 (<xref ref-type="bibr" rid="B17">Karsa et al., 2010</xref>). In the European Union (EU), as well as in Spain, CRC is the third leading newly diagnosed cancer, after lung cancer and prostate cancer in males and the second after breast cancer in females and the second leading cause of overall cancer deaths (<xref ref-type="bibr" rid="B16">Karim-Kos et al., 2008</xref>). Due to its high frequency, mortality and morbidity rates, and the high socio-economic burden associated with this disease, CRC has become an important and challenging public health problem (<xref ref-type="bibr" rid="B17">Karsa et al., 2010</xref>).</p><p>In the Basque Country (one of 17 Autonomous Regions of Spain), once age-adjusted at European standard population, CRC incidence (86.37/100,000 among men and 39.75/100,000 among women in 2009), and mortality rates (20.6/100,000 in 2009), have shown moderate increases, mainly in men from 1986 to 2008 (<xref ref-type="bibr" rid="B14">Izarzugaza et al., 2010</xref>).</p><p>Nowadays, a substantial amount of information is available on CRC etiology and prognosis. Its slow growth from benign lesions is currently well known and this makes many of these lesions detectable and removable at an early stage (<xref ref-type="bibr" rid="B27">Scottish Intercollegiate Guidelines Network [SIGN], 2011</xref>).</p><p>Primary prevention is based mainly on the adoption of healthy lifestyle measures including changes in dietary habits (<xref ref-type="bibr" rid="B15">Kahi et al., 2008</xref>). However, the benefits of both healthy lifestyle measures become visible in the long-term. It is therefore necessary to design and implement programs that allow early detection and management of pre-cancerous and cancer lesions (secondary prevention; <xref ref-type="bibr" rid="B37">von Karsa et al., 2008</xref>).</p><p>The new European Code against Cancer (2003/878/EC; <xref ref-type="bibr" rid="B9">European Code Against Cancer, 2012</xref>) includes among its recommendations that &#x0201c;men and women from 50 years of age and older should participate in CRC screening.&#x0201d; Both the EU and the Comprehensive Cancer Plan of the Spanish Ministry of Health, Social Services and Equity (2006; <xref ref-type="bibr" rid="B21">Ministerio de Sanidad y Pol&#x000ed;tica Social, 2010</xref>) include the implementation of screening programs among their recommendations for CRC prevention. Nationwide CRC screening programs are currently being implemented in several European countries as well as Spain. Effective screening methods have been shown to decrease CRC incidence rates by 20% and mortality rates by 33% (<xref ref-type="bibr" rid="B20">Mandel et al., 1993</xref>; <xref ref-type="bibr" rid="B29">Shaukat et al., 2013</xref>).</p><p>Up to now, the guaiac fecal occult blood test (g-FOBT) was considered the standard screening test used in CRC detection programs. However, recently marketed immunochemical tests (I-FOBT) have become widely accepted due to several advantages over g-FOBT (<xref ref-type="bibr" rid="B25">Rozen et al., 2009</xref>; <xref ref-type="bibr" rid="B24">Oono et al., 2010</xref>), and its use is recommended for population-based programs (<xref ref-type="bibr" rid="B28">Segnan et al., 2011</xref>). Advantages include a higher sensitivity, specificity for human hemoglobin (<xref ref-type="bibr" rid="B1">Allison et al., 2007</xref>), fewer stool samples required and no diet or medications restrictions are needed. Additionally, the quantitative nature of I-FOBT results allows for an optimal cut-off point to be set for a nationwide screening program (<xref ref-type="bibr" rid="B6">Castiglione et al., 2002</xref>; <xref ref-type="bibr" rid="B39">Wong et al., 2003</xref>; <xref ref-type="bibr" rid="B11">Fraser et al., 2006</xref>; <xref ref-type="bibr" rid="B12">Guittet et al., 2007</xref>; <xref ref-type="bibr" rid="B18">Levi et al., 2007</xref>), based on pre-specified criteria.</p><p>Adherence rate is of paramount importance to ensure CRC screening programs effectiveness. In this sense, immunochemical tests show higher adherence (<xref ref-type="bibr" rid="B7">Cole et al., 2003</xref>; <xref ref-type="bibr" rid="B33">Van Rossum et al., 2008</xref>; <xref ref-type="bibr" rid="B13">Hol et al., 2010</xref>) and detection rates (<xref ref-type="bibr" rid="B30">Smith et al., 2006</xref>; <xref ref-type="bibr" rid="B12">Guittet et al., 2007</xref>; <xref ref-type="bibr" rid="B33">Van Rossum et al., 2008</xref>) than g-FOBT.</p><p>The I-FOBT testing samples can be analyzed automatically, which involves important advantages in terms of quality assurance and costs (<xref ref-type="bibr" rid="B18">Levi et al., 2007</xref>).</p><p>The Basque Ministry of Health approved in 2008 the implementation of a population-based screening program through the detection of fecal occult blood (FOB) using I-FOBT as the screening method every 2 years and colonoscopy as a confirmation test. An important issue to be dealt with was decision on the particular I-FOBT to be used as two commercial diagnostic kits were available in the Spanish market at the time screening activities were about to start.</p><p>A comprehensive literature search did not yield consistent information regarding comparison of analytical and operational characteristics among marketed immunochemical tests. Just one journal article addressing the compared diagnostic efficacy of two different I-FOBTs was found, with no definitive results (<xref ref-type="bibr" rid="B26">Rubeca et al., 2006</xref>).</p><p>Therefore, we aimed to compare the two available I-FOBT tests: OC-Sensor (Eiken Chemical Co., Tokyo, Japan) and FOB Gold (Sentinel Diagnostics SpA, Milan, Italy) in terms of diagnostic performance, ease of use, acceptance, and operational features within the context of the pilot phase of a CRC population-based screening program. The outcomes of that study would then inform the decision-making process to choose the screening test for the ulterior full implementation.</p></sec><sec sec-type="methods" id="s1"><title>METHODS</title><p>This study involved the first round of a CRC population-based screening program in the Basque Country &#x02013; restricted to some previously determined health districts &#x02013; from January 2009 to March 2010, and invited residents aged 50&#x02013;69, from the Basque Health Service database (<italic>n</italic> = 37,999). People with colorectal cancer resection (CCR) history and who had undergone a previous colonoscopy within the past 5 years were excluded.</p><p>Participation was voluntary and was offered to all subjects residents who lived in the areas designated for the study and had a general practitioner (GP) assigned.</p><p>The Screening Management Centre sent a letter explaining the aims and methods of the screening program to all eligible subjects. After 7&#x02013;10 days, a second letter was sent with a request for them to participate in the program, including a kit package specifically suited to collect a single sample of feces, and stickers with the uptake&#x02019;s data to be attached to the tube. Participants could leave the kit sample at the Primary Care Centers during working hours (from 8:00 am to 8:00 pm). Samples were processed by trained laboratory staff following the instructions provided by the manufacturers. At health-district level, neither health professionals nor administrative staffs were aware that a comparison of screening kit tests was being conducted. Each assay test was randomly assigned by an independent researcher to each of five health districts where the program was being implemented. According to both manufacturer&#x02019;s instructions, tests were considered positive when the sample contained at least 100 ng/ml of hemoglobin by buffer. A colonoscopy was offered to all positive participants by their GP. When errors were identified by any laboratory before or after analyzing the sample, a new kit was sent to the participant and the new sample analyzed. True positives were defined by colonoscopy examination and pathology analysis. CRC screening performance measures were assessed following the National Guidelines published in 2009 (<xref ref-type="bibr" rid="B5">Castells et al., 2009</xref>). Every case was codified by expert staff in the Screening Management Centre. Advanced adenoma was considered: &#x0003e;10 mm, or 3&#x02013;10 adenomas or villous morphology, or high degree of dysplasia. Cancer colorectal was considered pT1.</p><p>This study was conducted under real practice conditions, which is why we did not perform colonoscopies for patients with a negative FOBT test. To control the false negatives interval cancers are followed, as recommended by the European Guidelines (<xref ref-type="bibr" rid="B37">von Karsa et al., 2008</xref>).</p><p>The study was submitted and approved by the Ethics Committees of screened areas.</p><sec><title>STATISTICAL ANALYSIS</title><p>Colorectal cancer screening performance measures were assessed following the European Guidelines (<xref ref-type="bibr" rid="B28">Segnan et al., 2011</xref>). Chi-square tests were used to compare proportions between relevant subgroups. Log-binomial regression models (<xref ref-type="bibr" rid="B3">Barros and Hirakata, 2003</xref>) were fitted to yield age and sex-adjusted comparisons among assessed kits, in terms of corresponding participation rates, positive predictive values, error rates, and cancer and advanced adenomas incidence rates. In order to assess magnitude and statistical significance of the effects of predictors of interest, average marginal effects (AME; mean change in predicted probabilities of the response variable across all sampled individuals when the categorical predictor changes by one level with respect to the reference level, keeping all other predictors at observed values) were calculated (<xref ref-type="bibr" rid="B4">Bartus, 2005</xref>). In some instances, to provide additional information on the magnitude of effects, relative estimates are given in the form of relative risks (RR) as estimates of prevalence ratios. Standard errors that took the cluster (health district assignment of kits) structure of the data into account were estimated using the delta method. Estimated models included statistically significant interactions. As gender&#x02013;age group interactions were most often encountered, AME are shown by gender and age stratum combinations to ease interpretation of effects. Significance level was set to 5%.</p><p>Statistical analyses were performed using Stata 12 for Windows (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP).</p></sec></sec><sec><title>RESULTS</title><sec><title>PROGRAM COVERAGE</title><p>The target population included 39,566 individuals. Finally, a total of 37,999 individuals aged 50&#x02013;69 and who met the participation criteria, were invited to participate. <bold>Table <xref ref-type="table" rid="T1">1</xref></bold> shows the characteristics of this population and performed procedures. Statistically significant differences in age distribution were found between invited individuals assigned to the study kits [mean age for population receiving FOB Gold 58.6 years (SD: 5.6) and 59.1 (5.8) for population receiving OC-Sensor; <italic>p</italic> = 0.000]. The same pattern of overall and strata-based age differences was found between individuals of both participants groups [mean age for FOB Gold 58.9 (5.5) and 59.5 (5.7) for OC-Sensor]. No statistically significant differences were found in gender distribution between invited people (50.2% of people receiving FOB Gold test were women vs. 50.8% in population receiving OC-sensor; <italic>p</italic> = 0.233).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Invited population, age, and sex distribution of participants and tests performed as a result of the screening program.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1">OC-Sensor<hr/></th><th valign="top" align="center" colspan="2" rowspan="1">FOB Gold<hr/></th><th valign="top" align="center" colspan="2" rowspan="1">Overall<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Mean</th><th valign="top" align="left" rowspan="1" colspan="1">SD</th><th valign="top" align="left" rowspan="1" colspan="1">Mean</th><th valign="top" align="left" rowspan="1" colspan="1">SD</th><th valign="top" align="left" rowspan="1" colspan="1">Mean</th><th valign="top" align="left" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (year) of invited individuals</td><td valign="top" align="left" rowspan="1" colspan="1">59.1</td><td valign="top" align="left" rowspan="1" colspan="1">5.8</td><td valign="top" align="left" rowspan="1" colspan="1">58.6</td><td valign="top" align="left" rowspan="1" colspan="1">5.6</td><td valign="top" align="left" rowspan="1" colspan="1">58.8</td><td valign="top" align="left" rowspan="1" colspan="1">5.7</td></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><th rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic></td><td valign="top" align="left" rowspan="1" colspan="1">%</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic></td><td valign="top" align="left" rowspan="1" colspan="1">%</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic></td><td valign="top" align="left" rowspan="1" colspan="1">%</td></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Invited population</td><td valign="top" align="left" rowspan="1" colspan="1">18,064</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">19,935</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">37,999</td><td valign="top" align="left" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Participants</td><td valign="top" align="left" rowspan="1" colspan="1">11,162</td><td valign="top" align="left" rowspan="1" colspan="1">61.8</td><td valign="top" align="left" rowspan="1" colspan="1">11,786</td><td valign="top" align="left" rowspan="1" colspan="1">59.1</td><td valign="top" align="left" rowspan="1" colspan="1">22,948</td><td valign="top" align="left" rowspan="1" colspan="1">60.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age distribution (year)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">50&#x02013;54</td><td valign="top" align="left" rowspan="1" colspan="1">2729</td><td valign="top" align="left" rowspan="1" colspan="1">24.5</td><td valign="top" align="left" rowspan="1" colspan="1">3163</td><td valign="top" align="left" rowspan="1" colspan="1">26.8</td><td valign="top" align="left" rowspan="1" colspan="1">5892</td><td valign="top" align="left" rowspan="1" colspan="1">25.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">55&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">2711</td><td valign="top" align="left" rowspan="1" colspan="1">24.3</td><td valign="top" align="left" rowspan="1" colspan="1">3156</td><td valign="top" align="left" rowspan="1" colspan="1">26.8</td><td valign="top" align="left" rowspan="1" colspan="1">5867</td><td valign="top" align="left" rowspan="1" colspan="1">25.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">60&#x02013;64</td><td valign="top" align="left" rowspan="1" colspan="1">3096</td><td valign="top" align="left" rowspan="1" colspan="1">27.7</td><td valign="top" align="left" rowspan="1" colspan="1">3169</td><td valign="top" align="left" rowspan="1" colspan="1">26.9</td><td valign="top" align="left" rowspan="1" colspan="1">6265</td><td valign="top" align="left" rowspan="1" colspan="1">27.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">65&#x02013;69</td><td valign="top" align="left" rowspan="1" colspan="1">2626</td><td valign="top" align="left" rowspan="1" colspan="1">23.5</td><td valign="top" align="left" rowspan="1" colspan="1">2298</td><td valign="top" align="left" rowspan="1" colspan="1">19.5</td><td valign="top" align="left" rowspan="1" colspan="1">4924</td><td valign="top" align="left" rowspan="1" colspan="1">21.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">5187</td><td valign="top" align="left" rowspan="1" colspan="1">46.5</td><td valign="top" align="left" rowspan="1" colspan="1">5529</td><td valign="top" align="left" rowspan="1" colspan="1">46.9</td><td valign="top" align="left" rowspan="1" colspan="1">10716</td><td valign="top" align="left" rowspan="1" colspan="1">46.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">5975</td><td valign="top" align="left" rowspan="1" colspan="1">53.5</td><td valign="top" align="left" rowspan="1" colspan="1">6257</td><td valign="top" align="left" rowspan="1" colspan="1">53.1</td><td valign="top" align="left" rowspan="1" colspan="1">12232</td><td valign="top" align="left" rowspan="1" colspan="1">53.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">I-FOBT results</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="left" rowspan="1" colspan="1">737</td><td valign="top" align="left" rowspan="1" colspan="1">6.6</td><td valign="top" align="left" rowspan="1" colspan="1">1,002</td><td valign="top" align="left" rowspan="1" colspan="1">8.5</td><td valign="top" align="left" rowspan="1" colspan="1">1,739</td><td valign="top" align="left" rowspan="1" colspan="1">7.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="left" rowspan="1" colspan="1">10,416</td><td valign="top" align="left" rowspan="1" colspan="1">93.3</td><td valign="top" align="left" rowspan="1" colspan="1">10,723</td><td valign="top" align="left" rowspan="1" colspan="1">91.0</td><td valign="top" align="left" rowspan="1" colspan="1">21,139</td><td valign="top" align="left" rowspan="1" colspan="1">92.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Result not available</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">0.1</td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1">0.5</td><td valign="top" align="left" rowspan="1" colspan="1">70</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Patients with colonoscopy performed</td><td valign="top" align="left" rowspan="1" colspan="1">686</td><td valign="top" align="left" rowspan="1" colspan="1">93.1<sup>1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">914</td><td valign="top" align="left" rowspan="1" colspan="1">91.2<sup>1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">1,600</td><td valign="top" align="left" rowspan="1" colspan="1">92.0<sup>1</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Colonoscopic result available</td><td valign="top" align="left" rowspan="1" colspan="1">686</td><td valign="top" align="left" rowspan="1" colspan="1">93.1<sup><xref ref-type="fn" rid="fn01">1</xref></sup></td><td valign="top" align="left" rowspan="1" colspan="1">912</td><td valign="top" align="left" rowspan="1" colspan="1">91.0<sup><xref ref-type="fn" rid="fn01">1</xref></sup></td><td valign="top" align="left" rowspan="1" colspan="1">1,598<sup><xref ref-type="fn" rid="fn02">2</xref></sup></td><td valign="top" align="left" rowspan="1" colspan="1">91.9<sup><xref ref-type="fn" rid="fn01">1</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="fn01"><label>1</label><p>Percentages of participants with the I-FOBT test positive;</p></fn><fn id="fn02"><label>2</label><p>1,576 colonoscopies with conclusive results.</p></fn></table-wrap-foot></table-wrap><p>Overall participation rate was 60.4% (OC-Sensor assay 61.8% vs. 59.1% for the FOB Gold, <italic>p</italic> = 0.008). It was consistently and significantly higher for females with an overall marginal effect estimate of 6.8% increase in participation rate relative to men (<bold>Tables <xref ref-type="table" rid="T1">2</xref></bold> and <bold><xref ref-type="table" rid="T3">3</xref></bold>). Participation rate with OC-Sensor test was higher for both sexes (65.1 vs. 62.6% in women and 58.3 vs. 55.6% in men) and kept consistently higher (range of differences: 1.5&#x02013;3.5%) across all age groups. However, this difference was not statistically significant when the cluster-randomized design was accounted for in the analysis (RR = 1.05; 95% CI = 0.93&#x02013;1.18) Participation rates increased significantly with age in both groups, showing a gradient which reached its highest value in those aged 60&#x02013;64. An interaction between gender and age was found in the two oldest strata, reflecting a larger increase in rates among men with stabilization in the oldest strata and a smaller increase among women aged 60&#x02013;64 with a moderate reduction in the oldest age group. Estimates of marginal effects on participation are, hence, presented separately by gender (<bold>Table <xref ref-type="table" rid="T3">3</xref></bold>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Results of participation rates and true positive rates by gender, age, and type of kit administered (true positive rates based on 1,576 colonoscopies performed with conclusive results).</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="3" rowspan="1">Female<hr/></th><th valign="top" align="center" colspan="3" rowspan="1">Male<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">OC-Sensor</th><th valign="top" align="left" rowspan="1" colspan="1">FOB Gold</th><th valign="top" align="left" rowspan="1" colspan="1">Total</th><th valign="top" align="left" rowspan="1" colspan="1">OC-Sensor</th><th valign="top" align="left" rowspan="1" colspan="1">FOB Gold</th><th valign="top" align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Participation rates (%)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1">65.1</td><td valign="top" align="left" rowspan="1" colspan="1">62.6</td><td valign="top" align="left" rowspan="1" colspan="1">63.8</td><td valign="top" align="left" rowspan="1" colspan="1">58.3</td><td valign="top" align="left" rowspan="1" colspan="1">55.6</td><td valign="top" align="left" rowspan="1" colspan="1">56.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age (year)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">50&#x02013;54</td><td valign="top" align="left" rowspan="1" colspan="1">59.5</td><td valign="top" align="left" rowspan="1" colspan="1">57.8</td><td valign="top" align="left" rowspan="1" colspan="1">58.5</td><td valign="top" align="left" rowspan="1" colspan="1">51.0</td><td valign="top" align="left" rowspan="1" colspan="1">49.7</td><td valign="top" align="left" rowspan="1" colspan="1">50.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">55&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">67.0</td><td valign="top" align="left" rowspan="1" colspan="1">63.6</td><td valign="top" align="left" rowspan="1" colspan="1">65.2</td><td valign="top" align="left" rowspan="1" colspan="1">57.6</td><td valign="top" align="left" rowspan="1" colspan="1">55.6</td><td valign="top" align="left" rowspan="1" colspan="1">56.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">60&#x02013;64</td><td valign="top" align="left" rowspan="1" colspan="1">69.3</td><td valign="top" align="left" rowspan="1" colspan="1">67.2</td><td valign="top" align="left" rowspan="1" colspan="1">68.2</td><td valign="top" align="left" rowspan="1" colspan="1">63.4</td><td valign="top" align="left" rowspan="1" colspan="1">59.9</td><td valign="top" align="left" rowspan="1" colspan="1">61.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">65&#x02013;69</td><td valign="top" align="left" rowspan="1" colspan="1">64.9</td><td valign="top" align="left" rowspan="1" colspan="1">62.5</td><td valign="top" align="left" rowspan="1" colspan="1">63.8</td><td valign="top" align="left" rowspan="1" colspan="1">62.8</td><td valign="top" align="left" rowspan="1" colspan="1">59.3</td><td valign="top" align="left" rowspan="1" colspan="1">61.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>True positive rates (%)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1">35.2</td><td valign="top" align="left" rowspan="1" colspan="1">31.0</td><td valign="top" align="left" rowspan="1" colspan="1">32.8</td><td valign="top" align="left" rowspan="1" colspan="1">54.3</td><td valign="top" align="left" rowspan="1" colspan="1">49.1</td><td valign="top" align="left" rowspan="1" colspan="1">51.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age (year)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">50&#x02013;54</td><td valign="top" align="left" rowspan="1" colspan="1">36.8</td><td valign="top" align="left" rowspan="1" colspan="1">32.9</td><td valign="top" align="left" rowspan="1" colspan="1">34.2</td><td valign="top" align="left" rowspan="1" colspan="1">41.7</td><td valign="top" align="left" rowspan="1" colspan="1">36.5</td><td valign="top" align="left" rowspan="1" colspan="1">38.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">55&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">33.3</td><td valign="top" align="left" rowspan="1" colspan="1">29.6</td><td valign="top" align="left" rowspan="1" colspan="1">31.3</td><td valign="top" align="left" rowspan="1" colspan="1">52.3</td><td valign="top" align="left" rowspan="1" colspan="1">44.5</td><td valign="top" align="left" rowspan="1" colspan="1">48.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">60&#x02013;64</td><td valign="top" align="left" rowspan="1" colspan="1">35.4</td><td valign="top" align="left" rowspan="1" colspan="1">31.3</td><td valign="top" align="left" rowspan="1" colspan="1">32.9</td><td valign="top" align="left" rowspan="1" colspan="1">56.9</td><td valign="top" align="left" rowspan="1" colspan="1">53.1</td><td valign="top" align="left" rowspan="1" colspan="1">54.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">65&#x02013;69</td><td valign="top" align="left" rowspan="1" colspan="1">35.8</td><td valign="top" align="left" rowspan="1" colspan="1">30.2</td><td valign="top" align="left" rowspan="1" colspan="1">32.9</td><td valign="top" align="left" rowspan="1" colspan="1">59.2</td><td valign="top" align="left" rowspan="1" colspan="1">57.5</td><td valign="top" align="left" rowspan="1" colspan="1">58.3</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Influence of the type of kit administered, gender and age on uptake and true positive rates.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="center" colspan="7" rowspan="1">Participation rates (%)<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Factor</th><th valign="top" align="left" rowspan="1" colspan="1">AME</th><th valign="top" align="left" rowspan="1" colspan="1">CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">6,8</td><td valign="top" align="left" rowspan="1" colspan="1">(5.9/7.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" align="center" colspan="4" rowspan="1"><bold>Males</bold><hr/></td><td valign="top" align="center" colspan="3" rowspan="1"><bold>Females</bold><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Factor</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>AME</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>CI</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>p</italic>-Value</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>AME</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>CI</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>p</italic>-Value</bold></td></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Kit</td><td valign="top" align="left" rowspan="1" colspan="1">2.6</td><td valign="top" align="left" rowspan="1" colspan="1">(-5.1/10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.513</td><td valign="top" align="left" rowspan="1" colspan="1">2.4</td><td valign="top" align="left" rowspan="1" colspan="1">(-4.8/9.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.512</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (55&#x02013;59)</td><td valign="top" align="left" rowspan="1" colspan="1">6.2</td><td valign="top" align="left" rowspan="1" colspan="1">(3.8/8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1">6.7</td><td valign="top" align="left" rowspan="1" colspan="1">(5.9/13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (60&#x02013;64)</td><td valign="top" align="left" rowspan="1" colspan="1">11.2</td><td valign="top" align="left" rowspan="1" colspan="1">(8.5/13.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1">9.6</td><td valign="top" align="left" rowspan="1" colspan="1">(5.9/13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (65&#x02013;69)</td><td valign="top" align="left" rowspan="1" colspan="1">10.7</td><td valign="top" align="left" rowspan="1" colspan="1">(6.2/15.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1">5.1</td><td valign="top" align="left" rowspan="1" colspan="1">(1.9/8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><bold>True positive rates</bold><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Factor</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>AME</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>CI</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>p</italic>-Value</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">-18.3</td><td valign="top" align="left" rowspan="1" colspan="1">(-22.1/-14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" align="center" colspan="4" rowspan="1"><bold>Males</bold><hr/></td><td valign="top" align="center" colspan="3" rowspan="1"><bold>Females</bold><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Factor</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>AME</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>CI</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>p</italic>-Value</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>AME</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>CI</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>p</italic>-Value</bold></td></tr><tr><td valign="top" align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Kit</td><td valign="top" align="left" rowspan="1" colspan="1">4.1</td><td valign="top" align="left" rowspan="1" colspan="1">(-0.4/8.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.074</td><td valign="top" align="left" rowspan="1" colspan="1">4.4</td><td valign="top" align="left" rowspan="1" colspan="1">(-4.9/13.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.354</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (55&#x02013;59)</td><td valign="top" align="left" rowspan="1" colspan="1">9.4</td><td valign="top" align="left" rowspan="1" colspan="1">(3.5/15.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1">-3.5</td><td valign="top" align="left" rowspan="1" colspan="1">(-11.7/4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.402</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (60&#x02013;64)</td><td valign="top" align="left" rowspan="1" colspan="1">16.1</td><td valign="top" align="left" rowspan="1" colspan="1">(11.7/20.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1">-1.7</td><td valign="top" align="left" rowspan="1" colspan="1">(-3.6/0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.096</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (65&#x02013;69)</td><td valign="top" align="left" rowspan="1" colspan="1">19.6</td><td valign="top" align="left" rowspan="1" colspan="1">(11.4/27.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1">-2.0</td><td valign="top" align="left" rowspan="1" colspan="1">(-12.8/8.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.721</td></tr></tbody></table><table-wrap-foot><attrib><italic>
Results are presented separately for men and women as there was evidence of interaction between gender and age. AME, average marginal effects; CI, 95% confidence intervals. Reference groups are males and 50&#x02013;54 years age group.</italic></attrib></table-wrap-foot></table-wrap></sec><sec><title>OUTCOMES WITH FECAL OCCULT BLOOD TESTING</title><p>Positive rate for OC-sensor was 6.6 and 8.5% for FOB Gold (RR = 0.77; 95% CI = 0.69&#x02013;0.87; <italic>p</italic> = 0.000). FOB Gold had consistently higher positive rates than OC-Sensor across all age and sex strata, except for women in the 54&#x02013;59 year age-group, where rates were very similar (OC-Sensor 4.6 vs. 4.5% for FOB Gold).</p><p>True positive rates were higher for OC-Sensor across all age-sex strata (<bold>Table <xref ref-type="table" rid="T2">2</xref></bold>). Due to age&#x02013;gender interaction, results are again shown separately for men and women. Among men this difference among kits was statistically significant on the relative scale (RR = 1.07; 95% CI = 1.00&#x02013;1.14) and marginally significant on absolute scale (<bold>Table <xref ref-type="table" rid="T3">3</xref></bold>). Among women differences were not statistically significant on either scale (RR = 1.04; 95% CI = 0.84&#x02013;1.29). Increasing age was significantly associated with substantially higher positive rates only among men (<bold>Table <xref ref-type="table" rid="T3">3</xref></bold>).</p><p>Significant differences were found between the compared kits in relation to the total number of errors [error rate for OC-Sensor 0.24% and for FOB Gold 2.35%, AME: -2.1 (-0.2/-4.0)]. Being female was marginally associated to a lower error rate [RR = 0.85 (0.72&#x02013;1.01), <italic>p</italic> = 0.06]. Increasing age was also associated to a higher error rate. Again there was interaction between age and sex, with the highest risk in men of 60&#x02013;64 years of age [RR = 1.62 (1.36&#x02013;1.92)] and in women of the 65&#x02013;69 years stratum [RR = 2.14 (1.71&#x02013;2.67)]. Most of the errors found in the case of FOB Gold were produced as a result of an incorrect sample manipulation by the participants.</p></sec><sec><title>OUTCOMES WITH COLONOSCOPY</title><p>The results of the colonoscopies are shown in Table <bold><xref ref-type="table" rid="T4">4</xref>.</bold> No significant differences were observed between OC-Sensor and FOB Gold groups. Although 80% of cancers detected in the OC-Sensor group were early cancers (stages I&#x02013;II) vs. 56.8% in the FOB Gold group, due to the small number of malignancies detected, this difference was not statistically significant.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Results of the colonoscopies and stage distribution of diagnosed cancers.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="3" rowspan="1">OC-Sensor<hr/></th><th valign="top" align="center" colspan="3" rowspan="1">FOB Gold<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic></th><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic></th><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p-value</italic></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">201</td><td valign="top" align="left" rowspan="1" colspan="1">29.3</td><td valign="top" align="left" rowspan="1" colspan="1">25.8&#x02013;32.8</td><td valign="top" align="left" rowspan="1" colspan="1">302</td><td valign="top" align="left" rowspan="1" colspan="1">33.1</td><td valign="top" align="left" rowspan="1" colspan="1">30.1&#x02013;36.3</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Polyp</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">5.7</td><td valign="top" align="left" rowspan="1" colspan="1">4.0&#x02013;7.7</td><td valign="top" align="left" rowspan="1" colspan="1">52</td><td valign="top" align="left" rowspan="1" colspan="1">5.7</td><td valign="top" align="left" rowspan="1" colspan="1">4.3&#x02013;7.4</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Not advanced adenoma</td><td valign="top" align="left" rowspan="1" colspan="1">106</td><td valign="top" align="left" rowspan="1" colspan="1">15.4</td><td valign="top" align="left" rowspan="1" colspan="1">12.8&#x02013;18.3</td><td valign="top" align="left" rowspan="1" colspan="1">156</td><td valign="top" align="left" rowspan="1" colspan="1">17.1</td><td valign="top" align="left" rowspan="1" colspan="1">14.7&#x02013;19.7</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Advanced adenoma</td><td valign="top" align="left" rowspan="1" colspan="1">282</td><td valign="top" align="left" rowspan="1" colspan="1">41.1</td><td valign="top" align="left" rowspan="1" colspan="1">37.4&#x02013;44.9</td><td valign="top" align="left" rowspan="1" colspan="1">338</td><td valign="top" align="left" rowspan="1" colspan="1">37.1</td><td valign="top" align="left" rowspan="1" colspan="1">33.9&#x02013;40.3</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cancer*</td><td valign="top" align="left" rowspan="1" colspan="1">35</td><td valign="top" align="left" rowspan="1" colspan="1">5.1</td><td valign="top" align="left" rowspan="1" colspan="1">3.6&#x02013;7.0</td><td valign="top" align="left" rowspan="1" colspan="1">44</td><td valign="top" align="left" rowspan="1" colspan="1">4.8</td><td valign="top" align="left" rowspan="1" colspan="1">3.6&#x02013;6.5</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage I</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">51.4</td><td valign="top" align="left" rowspan="1" colspan="1">35.1&#x02013;67.5</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">38.6</td><td valign="top" align="left" rowspan="1" colspan="1">24.4&#x02013;54.5</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage II</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">28.6</td><td valign="top" align="left" rowspan="1" colspan="1">15.5&#x02013;45.0</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">18.2</td><td valign="top" align="left" rowspan="1" colspan="1">8.2&#x02013;32.7</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage III</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">17.1</td><td valign="top" align="left" rowspan="1" colspan="1">7.2&#x02013;32.3</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">29.5</td><td valign="top" align="left" rowspan="1" colspan="1">16.8&#x02013;45.2</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage IV</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">2.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.7&#x02013;14.9</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">11.4</td><td valign="top" align="left" rowspan="1" colspan="1">3.8&#x02013;24.6</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;10.0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">2.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.06&#x02013;12.0</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-neoplasic pathology</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">1.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.5&#x02013;2.2</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">1.0</td><td valign="top" align="left" rowspan="1" colspan="1">0.4&#x02013;1.9</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inconclusive</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">2.2</td><td valign="top" align="left" rowspan="1" colspan="1">1.2&#x02013;3.6</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">1.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.6&#x02013;2.1</td><td valign="top" align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1">686</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">912</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><attrib><italic>n.s., non-significant. *Percentages for stages of cancer are based on the total number of cancers instead of total number of colonoscopies.</italic></attrib></table-wrap-foot></table-wrap><p><bold>Table <xref ref-type="table" rid="T5">5</xref></bold> shows the detection rates of advanced adenomas and cancerous lesions among screening participants. FOB Gold assay users showed higher rates overall and in most age-sex strata. Statistically significant interactions were found between type of kit and gender with age strata and, in order to ease interpretation of results, marginal predicted rates are used. Differences in marginal predictions were highly statistically significant according to type of kit assay (<italic>p</italic> = 0.000) with almost 10 more lesions detected with FOB Gold per 1,000 participants as compared to OC-Sensor. Being female was also strongly associated with a lower detection of pre-malignant and malignant lesions (<italic>p</italic> = 0.000) whereas increasing age was significantly associated with consistently higher detection rates (<italic>p</italic> = 0.000; <bold>Table <xref ref-type="table" rid="T5">5</xref></bold>).</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>(a) advanced adenoma and (b) cancer detection incidence rates according to gender, age group, and kit assay; (c) estimated marginal predictions of advanced adenomas and cancer detection rates according to gender, age group, and kit assay (based on health-district adjusted log binomial regression model including interactions between kit and gender with age group).</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="3" rowspan="1">Female<hr/></th><th valign="top" align="center" colspan="3" rowspan="1">Male<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">OC-Sensor</th><th valign="top" align="left" rowspan="1" colspan="1">FOB Gold</th><th valign="top" align="left" rowspan="1" colspan="1">Total</th><th valign="top" align="left" rowspan="1" colspan="1">OC-Sensor</th><th valign="top" align="left" rowspan="1" colspan="1">FOB Gold</th><th valign="top" align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>(a) Advanced adenoma detection rates (&#x02030;)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1">12.6</td><td valign="top" align="left" rowspan="1" colspan="1">14.3</td><td valign="top" align="left" rowspan="1" colspan="1">13.4</td><td valign="top" align="left" rowspan="1" colspan="1">39.8</td><td valign="top" align="left" rowspan="1" colspan="1">45.1</td><td valign="top" align="left" rowspan="1" colspan="1">42.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age (year)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">50&#x02013;54</td><td valign="top" align="left" rowspan="1" colspan="1">8.3</td><td valign="top" align="left" rowspan="1" colspan="1">12.9</td><td valign="top" align="left" rowspan="1" colspan="1">10.8</td><td valign="top" align="left" rowspan="1" colspan="1">18.6</td><td valign="top" align="left" rowspan="1" colspan="1">35.9</td><td valign="top" align="left" rowspan="1" colspan="1">21.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">55&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">13.1</td><td valign="top" align="left" rowspan="1" colspan="1">11.9</td><td valign="top" align="left" rowspan="1" colspan="1">12.5</td><td valign="top" align="left" rowspan="1" colspan="1">44.6</td><td valign="top" align="left" rowspan="1" colspan="1">35.9</td><td valign="top" align="left" rowspan="1" colspan="1">39.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">60&#x02013;64</td><td valign="top" align="left" rowspan="1" colspan="1">11.9</td><td valign="top" align="left" rowspan="1" colspan="1">14.8</td><td valign="top" align="left" rowspan="1" colspan="1">13.0</td><td valign="top" align="left" rowspan="1" colspan="1">45.3</td><td valign="top" align="left" rowspan="1" colspan="1">55.6</td><td valign="top" align="left" rowspan="1" colspan="1">50.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">65&#x02013;69</td><td valign="top" align="left" rowspan="1" colspan="1">17.2</td><td valign="top" align="left" rowspan="1" colspan="1">18.8</td><td valign="top" align="left" rowspan="1" colspan="1">17.9</td><td valign="top" align="left" rowspan="1" colspan="1">51.0</td><td valign="top" align="left" rowspan="1" colspan="1">70.7</td><td valign="top" align="left" rowspan="1" colspan="1">60.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>(b) Cancer detection rates (&#x02030;)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1">2.0</td><td valign="top" align="left" rowspan="1" colspan="1">2.4</td><td valign="top" align="left" rowspan="1" colspan="1">2.2</td><td valign="top" align="left" rowspan="1" colspan="1">4.4</td><td valign="top" align="left" rowspan="1" colspan="1">5.2</td><td valign="top" align="left" rowspan="1" colspan="1">4.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age (year)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">50&#x02013;54</td><td valign="top" align="left" rowspan="1" colspan="1">1.4</td><td valign="top" align="left" rowspan="1" colspan="1">2.9</td><td valign="top" align="left" rowspan="1" colspan="1">2.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td><td valign="top" align="left" rowspan="1" colspan="1">2.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">55&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">1.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td><td valign="top" align="left" rowspan="1" colspan="1">5.4</td><td valign="top" align="left" rowspan="1" colspan="1">3.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">60&#x02013;64</td><td valign="top" align="left" rowspan="1" colspan="1">1.8</td><td valign="top" align="left" rowspan="1" colspan="1">3.0</td><td valign="top" align="left" rowspan="1" colspan="1">2.4</td><td valign="top" align="left" rowspan="1" colspan="1">7.1</td><td valign="top" align="left" rowspan="1" colspan="1">2.7</td><td valign="top" align="left" rowspan="1" colspan="1">4.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">65&#x02013;69</td><td valign="top" align="left" rowspan="1" colspan="1">3.6</td><td valign="top" align="left" rowspan="1" colspan="1">3.4</td><td valign="top" align="left" rowspan="1" colspan="1">3.5</td><td valign="top" align="left" rowspan="1" colspan="1">8.9</td><td valign="top" align="left" rowspan="1" colspan="1">11.6</td><td valign="top" align="left" rowspan="1" colspan="1">10.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>(c) Marginal predicted detection rates (&#x02030;)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Gender</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Predicted</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>95% CI</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">68.4</td><td valign="top" align="left" rowspan="1" colspan="1">64.8&#x02013;72.0</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">40.8</td><td valign="top" align="left" rowspan="1" colspan="1">37.9&#x02013;43.7</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age (year)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">50&#x02013;54</td><td valign="top" align="left" rowspan="1" colspan="1">28.4</td><td valign="top" align="left" rowspan="1" colspan="1">26.5&#x02013;30.3</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">55&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">43.2</td><td valign="top" align="left" rowspan="1" colspan="1">37.7&#x02013;48.7</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">60&#x02013;64</td><td valign="top" align="left" rowspan="1" colspan="1">50.4</td><td valign="top" align="left" rowspan="1" colspan="1">46.6&#x02013;54.3</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">65&#x02013;69</td><td valign="top" align="left" rowspan="1" colspan="1">64.0</td><td valign="top" align="left" rowspan="1" colspan="1">57.8&#x02013;70.1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Kit</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FOB Gold</td><td valign="top" align="left" rowspan="1" colspan="1">50.6</td><td valign="top" align="left" rowspan="1" colspan="1">49.0&#x02013;52.3</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OC-Sensor</td><td valign="top" align="left" rowspan="1" colspan="1">40.8</td><td valign="top" align="left" rowspan="1" colspan="1">37.9&#x02013;43.8</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec></sec><sec><title>DISCUSSION</title><p>When a population-based screening program is to be implemented, one key issue to deal with is selection of the screening test to use. In the Basque Country initial decision considered that the population-based CRC screening program was to be based on I-FOBT. Accordingly, in the context of a progressive implementation of the CRC population-based program, a quasi-experimental study has been carried out aimed to compare the diagnostic accuracy and operational characteristics of the two available marketed I-FOBT tests, FOB Gold and OC-Sensor. Manufacturers&#x02019; recommended cut-off levels have been used (<xref ref-type="bibr" rid="B35">Vilkin et al., 2005</xref>; <xref ref-type="bibr" rid="B26">Rubeca et al., 2006</xref>; <xref ref-type="bibr" rid="B18">Levi et al., 2007</xref>). In our study, several remarkable differences have been found between the diagnostic kits compared. It may be possibly attributable to differences in the quantity of buffer and other features (<xref ref-type="bibr" rid="B23">NHS Purchasing and Supply Agency, 2009</xref>; <xref ref-type="bibr" rid="B22">Moss et al., 2010</xref>).</p><p>Overall participation rate (60.4%) in this pilot program is well above the minimum acceptable recommended (<xref ref-type="bibr" rid="B28">Segnan et al., 2011</xref>) and similar or higher than reported rates in other pilot or established screening programs (<xref ref-type="bibr" rid="B31">UK Colorectal Cancer Screening Pilot Group, 2004</xref>; <xref ref-type="bibr" rid="B8">Department of Health, 2006</xref>; <xref ref-type="bibr" rid="B19">M&#x000e1;laga L&#x000f3;pez et al., 2010</xref>). This may be partly attributed to the use of an invitation approach based on mail contact with the target population that included sending the fecal sampling kit (<xref ref-type="bibr" rid="B32">Van Roosbroeck et al., 2012</xref>). Participation rates were almost 7% higher in women and increased with aging in both sexes reaching a peak in the 60&#x02013;64 age group. This result is in agreement with most but not all FOBT-based screening programs conducted in Europe and Australia (<xref ref-type="bibr" rid="B36">Von Euler-Chelpin et al., 2010</xref>; <xref ref-type="bibr" rid="B2">Australian Institute of Health and Welfare, 2012</xref>). There was a significant decline in participation among women of the oldest group, but not among men. Other papers have reported a drop in participation rates in oldest age groups as well (<xref ref-type="bibr" rid="B36">Von Euler-Chelpin et al., 2010</xref>). This finding cannot be compared with results from the single published randomized comparison of diagnostic performance of both tests (<xref ref-type="bibr" rid="B26">Rubeca et al., 2006</xref>) as participation required using both diagnostic kits simultaneously. However, one of the main strengths of our study is that it was conducted in standard of care conditions.</p><p>The use of OC-Sensor assay resulted in a consistently increased but not statistically significant absolute participation rates of around 2&#x02013;3% which might have actual practical relevance though. Gender and age-related participation patterns were similar for both assays. As we did not survey participants or qualitatively analyzed on individual characteristics or potentially relevant operational issues such as ease of use of received kits or other factors, we cannot make any conclusive statement about the reasons for this observed differences. Rates of positive tests were higher than referred in most screening programs that employed any of these tests with 100 ng/ml as cut-off level on average-risk individuals (<xref ref-type="bibr" rid="B6">Castiglione et al., 2002</xref>; <xref ref-type="bibr" rid="B26">Rubeca et al., 2006</xref>). Rates were significantly higher among FOB Gold users which resulted in this group undertaking an increased amount of colonoscopies (26% increases) compared to OC-Sensor users. These results are in conflict with the work by <xref ref-type="bibr" rid="B26">Rubeca et al. (2006)</xref> which found slightly higher positive diagnostic rates among OC-Sensor users. Several screening strategies have established different cut-off points for positive results using OC-Sensor assay (<xref ref-type="bibr" rid="B34">Van Rossum et al., 2009</xref>; <xref ref-type="bibr" rid="B38">Wilschut et al., 2011</xref>; <xref ref-type="bibr" rid="B10">Faivre et al., 2012</xref>), 50&#x02013;75 ng/ml, but in our population, based on observed positivity rates, lowering the cut-off may not be appropriate without careful consideration of the amount of extra resources (colonoscopy and pathology procedures) involved and the iatrogenic consequences of false positives.</p><p>With regard to true positive rates (positive predictive values), several results are remarkable. First of all, true positive rates were much higher among men across all age strata. Secondly the use of OC-Sensor assay was associated with higher rates. The higher percentage of participation found among women when compared to men across all age levels is according with other studies (<xref ref-type="bibr" rid="B31">UK Colorectal Cancer Screening Pilot Group, 2004</xref>; <xref ref-type="bibr" rid="B8">Department of Health, 2006</xref>; <xref ref-type="bibr" rid="B19">M&#x000e1;laga L&#x000f3;pez et al., 2010</xref>; <xref ref-type="bibr" rid="B22">Moss et al., 2010</xref>). Participation with OC-Sensor was higher than with FOB Gold, for both sexes and across all age groups, but this differences were not statistically significant when the health-district unit of assignment was considered in the analysis.</p><p>With respect to the relationship between age and participation, most studies indicated an inverted &#x0201c;U&#x0201d; shaped function with lowest rates of participation in 50&#x02013;55 years old and those 70&#x02013;80 (<xref ref-type="bibr" rid="B2">Australian Institute of Health and Welfare, 2012</xref>; <xref ref-type="bibr" rid="B10">Faivre et al., 2012</xref>). Our results, although do not include individuals 70 years of age and older, seem to be in agreement with this functional relationship.</p><p>A differential gender pattern of true positive responses was found. Whereas among women neither age nor the kit utilized influenced the probability that a positive result was in fact due to a premalignant or malignant lesion detectable by colonoscopy, among men increasing age and the use of OC-Sensor kit were associated to a higher prevalence of true positives.</p><p>We have also observed that gender and age are related to differences in the detection rates of advanced adenomas and cancer; with higher rates in men and higher rates by age group. We have observed that in our population detections rates of adenomas are higher than in other studies (<xref ref-type="bibr" rid="B4">Bartus, 2005</xref>; <xref ref-type="bibr" rid="B35">Vilkin et al., 2005</xref>; <xref ref-type="bibr" rid="B30">Smith et al., 2006</xref>). When we analyze the results by type of kit with FOB Gold we can conclude that: on the one hand, it has higher rate of positive values, with more colonoscopies performed, and on the other hand, it shows higher detection rate but involves more false positives.</p><p>We believe the strengths of this study include quasi-experimental design, comparison of two I-FOBT tests following manufacturer&#x02019;s recommendations.</p><p>Possible Limitations of the study: (i) cluster randomized design with small number of clusters leading to baseline imbalance (but we have used analytical techniques that take clustering effect into consideration) (ii) lack of measurement on potentially important covariates either at individual level (socioeconomic level, education, etc.) or at cluster level (deprivation index, ethnic distribution, etc.). As a result there might be important predictors confounding the estimates of effect of the type of kit used. The characteristics of the baseline population in the Basque Country (homogeneity) and the randomization of the assignment of the kits could counterbalance the effects of this lack of measurement.</p></sec><sec><title>CONCLUSION</title><p>OC-Sensor test appears to be superior for I-FOBT-based CRC screening, given its acceptance, ease of use, associated small number of errors and its screening accuracy. The goal of screening programs is the early detection and removal of neoplasms and, above all, the secondary prevention of colorectal cancer in the general population. Although the interval cancer period is required to establish a proper comparison, the advantages found in this analysis are consistent and lead to the selection of OC sensor as the kit to be used in the CRC population-based program in our region.</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>The authors would like to express our gratitude to Osakidetza, the Basque Health Service, for their support invaluable and collaboration. We would also like to thank the technical personnel of the various institutions involved, and especially all the participants who kindly agreed to take part in this study. We also thank the invaluable collaboration of Primary Care staff who is the main cause of these successful results in the screening program.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>J. E.</given-names></name><name><surname>Sakoda</surname><given-names>L. C.</given-names></name><name><surname>Levin</surname><given-names>T. R.</given-names></name><name><surname>Tucker</surname><given-names>J. P.</given-names></name><name><surname>Tekawa</surname><given-names>I. S.</given-names></name><name><surname>Cuff</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.</article-title>
<source><italic>J. Natl. Cancer Inst.</italic></source>
<volume>99</volume>
<fpage>1462</fpage>&#x02013;<lpage>1470</lpage><pub-id pub-id-type="doi">10.1093/jnci/djm150</pub-id><pub-id pub-id-type="pmid">17895475</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="book"><collab>Australian Institute of Health and Welfare.</collab> (<year>2012</year>). <source><italic>National Bowel Cancer Screening Program Monitoring Report: Phase 2, July 2008&#x02013;June 2011</italic>.</source>
<publisher-loc>Cancer Series NO. 65. Cat. No. CAN 61. Canberra</publisher-loc>: <publisher-name>AIHW.</publisher-name>
<comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737421401"/> (accessed on September 5, 2013)</comment></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barros</surname><given-names>A. J. D.</given-names></name><name><surname>Hirakata</surname><given-names>V. N.</given-names></name></person-group> (<year>2003</year>). <article-title>Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio.</article-title>
<source><italic>BMC Med. Res. Methodol.</italic></source>
<volume>3</volume>:<issue>21</issue><pub-id pub-id-type="doi">10.1186/1471-2288-3-21</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartus</surname><given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>Estimation of marginal effects using margeff.</article-title>
<source><italic>Stata J.</italic></source>
<volume>3</volume>
<fpage>309</fpage>&#x02013;<lpage>329</lpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castells</surname><given-names>A.</given-names></name><name><surname>Mar-Castillejo</surname><given-names>M.</given-names></name><name><surname>Mascort</surname><given-names>J. J.</given-names></name><name><surname>Amador</surname><given-names>F. J.</given-names></name><name><surname>Giraldez</surname><given-names>M. D.</given-names></name><name><surname>Andreu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Gu&#x000ef;a de Pr&#x000e1;ctica Cl&#x000ef;nica.</article-title>
<source>Prevenci&#x000f3;n del C&#x000e1;ncer Colorrectal. Update 2009. <italic>Gastroenterol. Hepatol.</italic></source>
<volume>32</volume>
<fpage>717</fpage>&#x02013;<lpage>758</lpage></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castiglione</surname><given-names>G.</given-names></name><name><surname>Grazzini</surname><given-names>G.</given-names></name><name><surname>Miccinesi</surname><given-names>G.</given-names></name><name><surname>Rubeca</surname><given-names>T.</given-names></name><name><surname>Sani</surname><given-names>C.</given-names></name><name><surname>Turco</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood.</article-title>
<source><italic>J. Med. Screen.</italic></source>
<volume>9</volume>
<fpage>99</fpage>&#x02013;<lpage>103</lpage><pub-id pub-id-type="doi">10.1136/jms.9.3.99</pub-id><pub-id pub-id-type="pmid">12370319</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>S. R.</given-names></name><name><surname>Young</surname><given-names>G. P.</given-names></name><name><surname>Esterman</surname><given-names>A.</given-names></name><name><surname>Cadd</surname><given-names>B.</given-names></name><name><surname>Morcom</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer.</article-title>
<source><italic>J. Med. Screen.</italic></source>
<volume>10</volume>
<fpage>117</fpage>&#x02013;<lpage>122</lpage><pub-id pub-id-type="doi">10.1258/096914103769011003</pub-id><pub-id pub-id-type="pmid">14561262</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="book"><collab>Department of Health.</collab> (<year>2006</year>). <source><italic>English Pilot of Bowel Cancer Screening: An Evaluation of the Second Round</italic>.</source>
<publisher-loc>London</publisher-loc>: <publisher-name>Institute of Cancer Research.</publisher-name>
<comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.cancerscreening.nhs.uk/bowel/pilot-2nd-round-evaluation.pdf"/> (accessed June 20, 2013)</comment></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><collab>European Code Against Cancer.</collab> (<year>2012</year>). <source><italic>European Code Against Cancer, 3rd Version.</italic></source>
<comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/health-eu/doc/cancercode_en.pdf"/> (accessed June 20, 2013)</comment></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname><given-names>J.</given-names></name><name><surname>Dancourt</surname><given-names>V.</given-names></name><name><surname>Denis</surname><given-names>B.</given-names></name><name><surname>Dorval</surname><given-names>E.</given-names></name><name><surname>Piette</surname><given-names>C.</given-names></name><name><surname>Perrin</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer.</article-title>
<source><italic>Eur. J. Cancer</italic></source>
<volume>48</volume>
<fpage>2969</fpage>&#x02013;<lpage>2976</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2012.04.007</pub-id><pub-id pub-id-type="pmid">22572481</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>C. G.</given-names></name><name><surname>Mathew</surname><given-names>C. M.</given-names></name><name><surname>Mowat</surname><given-names>N. A. G.</given-names></name><name><surname>Wilson</surname><given-names>A.</given-names></name><name><surname>Carey</surname><given-names>F. A.</given-names></name><name><surname>Steele</surname><given-names>R. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programmeme for colorectal cancer: an observational study.</article-title>
<source><italic>Lancet Oncol.</italic></source>
<volume>7</volume>
<fpage>127</fpage>&#x02013;<lpage>131</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(05)70473-3</pub-id><pub-id pub-id-type="pmid">16455476</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guittet</surname><given-names>L.</given-names></name><name><surname>Bouvier</surname><given-names>V.</given-names></name><name><surname>Mariotte</surname><given-names>N.</given-names></name><name><surname>Vallee</surname><given-names>J. P.</given-names></name></person-group> Ars&#x000e8;<person-group person-group-type="author"><name><surname>ne</surname><given-names>D.</given-names></name><name><surname>Boutreux</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.</article-title>
<source><italic>Gut</italic></source>
<volume>56</volume>
<fpage>210</fpage>&#x02013;<lpage>214</lpage><pub-id pub-id-type="doi">10.1136/gut.2006.101428</pub-id><pub-id pub-id-type="pmid">16891354</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hol</surname><given-names>L.</given-names></name><name><surname>de Jonge</surname><given-names>V.</given-names></name><name><surname>van Leerdam</surname><given-names>M. E.</given-names></name><name><surname>van Ballegooijen</surname><given-names>M.</given-names></name><name><surname>Looman</surname><given-names>C. W.</given-names></name><name><surname>van Vuuren</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy.</article-title>
<source><italic>Eur. J. Cancer</italic></source>
<volume>46</volume>
<fpage>2059</fpage>&#x02013;<lpage>2066</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2010.03.022</pub-id><pub-id pub-id-type="pmid">20621736</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Izarzugaza</surname><given-names>M. I.</given-names></name><name><surname>Mart&#x000ef;nez</surname><given-names>R.</given-names></name><name><surname>Aud&#x000ef;cana</surname><given-names>C.</given-names></name><name><surname>Larra&#x000f1;aga</surname><given-names>N.</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>E.</given-names></name><name><surname>Tobalina</surname><given-names>M. C.</given-names></name><etal/></person-group> (<year>2010</year>). <source><italic>El C&#x000e1;ncer en el Pa&#x000ef;s Vasco Incidencia, Mortalidad, Supervivencia y Evoluci&#x000f3;n Temporal.</italic></source>
<publisher-loc>Vitoria-Gasteiz</publisher-loc>: <publisher-name>Department of Health of the Basque Government, Servicio Central de Publicaciones del Gobierno Vasco, 126.</publisher-name>
<comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.osakidetza.euskadi.net/r85-20319/es/contenidos/informacion/estado_salud/es_5463/adjuntos/cancer.pdf"/> (accessed June 20, 2013)</comment></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahi</surname><given-names>C. J.</given-names></name><name><surname>Rex</surname><given-names>D. K.</given-names></name><name><surname>Imperiale</surname><given-names>T. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>135</volume>
<fpage>380</fpage>&#x02013;<lpage>399</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.06.026</pub-id><pub-id pub-id-type="pmid">18582467</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karim-Kos</surname><given-names>H. E.</given-names></name><name><surname>de Vries</surname><given-names>E.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Lemmens</surname><given-names>V.</given-names></name><name><surname>Siesling</surname><given-names>S.</given-names></name><name><surname>Coebergh</surname><given-names>J. W.</given-names></name></person-group> (<year>2008</year>). <article-title>Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s.</article-title>
<source><italic>Eur. J. Cancer</italic></source>
<volume>44</volume>
<fpage>1345</fpage>&#x02013;<lpage>1389</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2007.12.015</pub-id><pub-id pub-id-type="pmid">18280139</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsa</surname><given-names>L. V.</given-names></name><name><surname>Lignini</surname><given-names>T. A.</given-names></name><name><surname>Patnick</surname><given-names>J.</given-names></name><name><surname>Lambert</surname><given-names>R.</given-names></name><name><surname>Sauvaget</surname><given-names>C.</given-names></name></person-group> (<year>2010</year>). <article-title>The dimensions of the CRC problem.</article-title>
<source><italic>Best Pract. Res. Clin. Gastroenterol.</italic></source>
<volume>24</volume>
<fpage>381</fpage>&#x02013;<lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.bpg.2010.06.004</pub-id><pub-id pub-id-type="pmid">20833343</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>Z.</given-names></name><name><surname>Rozen</surname><given-names>P.</given-names></name><name><surname>Hazazi</surname><given-names>R.</given-names></name><name><surname>Vilkin</surname><given-names>A.</given-names></name><name><surname>Waked</surname><given-names>A.</given-names></name><name><surname>Maoz</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>A quantitative immunochemical fecal occult blood test for colorectal neoplasia.</article-title>
<source><italic>Ann. Intern. Med.</italic></source>
<volume>146</volume>
<fpage>244</fpage>&#x02013;<lpage>255</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-146-4-200702200-00003</pub-id><pub-id pub-id-type="pmid">17310048</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e1;laga L&#x000f3;pez</surname><given-names>A.</given-names></name><name><surname>Salas Trejo</surname><given-names>D.</given-names></name><name><surname>Sala Felis</surname><given-names>T.</given-names></name><name><surname>Ponce Romero</surname><given-names>M.</given-names></name><name><surname>Goicoechea S&#x000e1;ez</surname><given-names>M</given-names></name><name><surname>Andr&#x000e9;s Mart&#x000ef;nez</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Programa de Cribado de C&#x000e1;ncer Colorrectal de la Comunidad Valenciana. Resultados de la Primera Ronda: 2005&#x02013;2008.</article-title>
<source><italic>Rev. Esp. Salud P&#x000fa;blica</italic></source>
<volume>84</volume>
<fpage>729</fpage>&#x02013;<lpage>741</lpage></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname><given-names>J. S.</given-names></name><name><surname>Bond</surname><given-names>J. H.</given-names></name><name><surname>Church</surname><given-names>T. R.</given-names></name><name><surname>Snover</surname><given-names>D. C.</given-names></name><name><surname>Bradley</surname><given-names>G. M.</given-names></name><name><surname>Schuman</surname><given-names>L. M.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Reducing mortality from colorectal cancer by screening for fecal occult blood.</article-title>
<source>Minnesota Colon Cancer Control Study. <italic>N. Engl. J. Med.</italic></source>
<volume>328</volume>
<fpage>1365</fpage>&#x02013;<lpage>1371</lpage><pub-id pub-id-type="doi">10.1056/NEJM199305133281901</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="book"><collab>Ministerio de Sanidad y Pol&#x000ef;tica Social.</collab> (<year>2010</year>). <source><italic>Estrategia de C&#x000e1;ncer del Sistema Nacional de Salud.</italic></source>
<publisher-loc>Madrid</publisher-loc>: <publisher-name>Centro de publicaciones del Ministerio de Sanidad y Pol&#x000ef;tica Social.</publisher-name> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.msssi.gob.es/organizacion/sns/planCalidadSNS/pdf/ActualizacionEstrategiaCancer.pdf"/>
<comment>(accessed June 20, 2013)</comment></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>S.</given-names></name><name><surname>Ancell-Park</surname><given-names>R.</given-names></name><name><surname>Brenner</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>). <article-title>&#x0201c;Evaluation and interpretation of screening outcomes,&#x0201d; in</article-title>
<source><italic>European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis</italic></source>
<edition>1st edn</edition>
<role>eds</role>
<person-group person-group-type="editor"><name><surname>Segnan</surname><given-names>N.</given-names></name><name><surname>Patnick</surname><given-names>J.</given-names></name><name><surname>von Karsa</surname><given-names>L.</given-names></name></person-group> (<publisher-loc>Luxembourg</publisher-loc>: <publisher-name>Publications Office of the European Union</publisher-name>) <fpage>71</fpage>&#x02013;<lpage>102</lpage></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="book"><collab>NHS Purchasing and Supply Agency.</collab> (<year>2009</year>). <source><italic>Evaluation Report: Immunochemical Faecal Occult Blood Test.</italic></source>
<publisher-loc>London</publisher-loc>: <publisher-name>Center for Evidence-based Purchasing.</publisher-name> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.cancerscreening.nhs.uk/bowel/ifobt.pdf"/>
<comment>(accessed June 20, 2013)</comment></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oono</surname><given-names>Y.</given-names></name><name><surname>Iriguchi</surname><given-names>Y.</given-names></name><name><surname>Doi</surname><given-names>Y.</given-names></name><name><surname>Tomino</surname><given-names>Y.</given-names></name><name><surname>Kishi</surname><given-names>D.</given-names></name><name><surname>Oda</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>A retrospective study of immunochemical fecal blood testing for colorectal cancer detection.</article-title>
<source><italic>Clin. Chim. Acta</italic></source>
<volume>411</volume>
<fpage>802</fpage>&#x02013;<lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2010.02.057</pub-id><pub-id pub-id-type="pmid">20184867</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozen</surname><given-names>P.</given-names></name><name><surname>Levi</surname><given-names>Z.</given-names></name><name><surname>Hazazi</surname><given-names>R.</given-names></name><name><surname>Waked</surname><given-names>A.</given-names></name><name><surname>Vilkin</surname><given-names>A.</given-names></name><name><surname>Maoz</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.</article-title>
<source><italic>Aliment. Pharmacol. Ther.</italic></source>
<volume>29</volume>
<fpage>450</fpage>&#x02013;<lpage>457</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2008.03898.x</pub-id><pub-id pub-id-type="pmid">19035980</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubeca</surname><given-names>T.</given-names></name><name><surname>Rapi</surname><given-names>S.</given-names></name><name><surname>Confortini</surname><given-names>M.</given-names></name><name><surname>Brogioni</surname><given-names>M.</given-names></name><name><surname>Grazzini</surname><given-names>G.</given-names></name><name><surname>Zappa</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT).</article-title>
<source>Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. <italic>Int. J. Biol. Markers</italic></source>
<volume>21</volume>
<fpage>157</fpage>&#x02013;<lpage>161</lpage></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="book"><collab>Scottish Intercollegiate Guidelines Network (SIGN).</collab> (<year>2011</year>). <source><italic>Diagnosis and Management of Colorectal Cancer</italic>.</source>
<publisher-loc>SIGN Publication No. 126. Edinburgh</publisher-loc>: <publisher-name>SIGN.</publisher-name> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.sign.ac.uk/pdf/sign126.pdf"/>
<comment>(accessed December 2011)</comment></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segnan</surname><given-names>N.</given-names></name><name><surname>Patnick</surname><given-names>J</given-names></name><name><surname>von Karsa</surname><given-names>L.</given-names></name></person-group> (<year>eds</year>). <article-title>(2011).</article-title>
<source><italic>European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis</italic>. Brussels: European</source>
<volume>Commission</volume>
<issue>386</issue></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaukat</surname><given-names>A.</given-names></name><name><surname>Mongin</surname><given-names>S.</given-names></name><name><surname>Geisser</surname><given-names>M.</given-names></name><name><surname>Lederle</surname><given-names>F. A.</given-names></name><name><surname>Bond</surname><given-names>J. H.</given-names></name><name><surname>Mandel</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Long-term mortality after screening for colorectal cancer.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>369</volume>
<fpage>1106</fpage>&#x02013;<lpage>1114</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1300720</pub-id><pub-id pub-id-type="pmid">24047060</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>A.</given-names></name><name><surname>Young</surname><given-names>G.</given-names></name><name><surname>Cole</surname><given-names>S.</given-names></name><name><surname>Bampton</surname><given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>Comparison of a brush sampling fecal immunochemical test for haemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.</article-title>
<source><italic>Cancer</italic></source>
<volume>107</volume>
<fpage>2152</fpage>&#x02013;<lpage>2159</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.22230</pub-id><pub-id pub-id-type="pmid">16998938</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><collab>UK Colorectal Cancer Screening Pilot Group.</collab> (<year>2004</year>). <article-title>Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.</article-title>
<source><italic>BMJ</italic></source>
<volume>329</volume>
<fpage>133</fpage>&#x02013;<lpage>137</lpage><pub-id pub-id-type="doi">10.1136/bmj.38153.491887.7C</pub-id><pub-id pub-id-type="pmid">15237087</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Roosbroeck</surname><given-names>S.</given-names></name><name><surname>Hoeck</surname><given-names>S</given-names></name><name><surname>Van Hal</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.</article-title>
<source><italic>Cancer Epidemiol.</italic></source>
<volume>36</volume>
<fpage>e317</fpage>&#x02013;<lpage>e324</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2012.04.003</pub-id><pub-id pub-id-type="pmid">22560885</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Rossum</surname><given-names>L. G.</given-names></name><name><surname>Van Rijn</surname><given-names>A. F.</given-names></name><name><surname>Laheij</surname><given-names>R. J.</given-names></name><name><surname>Van Oijen</surname><given-names>M. G.</given-names></name><name><surname>Fockens</surname><given-names>P.</given-names></name><name><surname>Van Krieken</surname><given-names>H. H.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>135</volume>
<fpage>82</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.03.040</pub-id><pub-id pub-id-type="pmid">18482589</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Rossum</surname><given-names>L. G. M.</given-names></name><name><surname>van Rijn</surname><given-names>A. F.</given-names></name><name><surname>Laheij</surname><given-names>R. J. F.</given-names></name><name><surname>van Oijen</surname><given-names>M. G.</given-names></name><name><surname>Fockens</surname><given-names>P.</given-names></name><name><surname>Jansen</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme.</article-title>
<source><italic>Br. J. Cancer</italic></source>
<volume>101</volume>
<fpage>1274</fpage>&#x02013;<lpage>1281</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605326</pub-id><pub-id pub-id-type="pmid">19755997</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilkin</surname><given-names>A.</given-names></name><name><surname>Rozen</surname><given-names>P.</given-names></name><name><surname>Levi</surname><given-names>Z.</given-names></name><name><surname>Waked</surname><given-names>A.</given-names></name><name><surname>Maoz</surname><given-names>E.</given-names></name><name><surname>Birkenfeld</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.</article-title>
<source><italic>Am. J. Gastroenterol.</italic></source>
<volume>100</volume>
<fpage>2519</fpage>&#x02013;<lpage>2525</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.00231.x</pub-id><pub-id pub-id-type="pmid">16279909</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Euler-Chelpin</surname><given-names>M.</given-names></name><name><surname>Brasso</surname><given-names>K.</given-names></name><name><surname>Lynge</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Determinants of participation in colorectal cancer screening with faecal occult blood testing.</article-title>
<source><italic>J. Public Health</italic></source>
<volume>32</volume>
<fpage>395</fpage>&#x02013;<lpage>405</lpage><pub-id pub-id-type="doi">10.1093/pubmed/fdp115</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>von Karsa</surname><given-names>L.</given-names></name><name><surname>Anttila</surname><given-names>A.</given-names></name><name><surname>Ronco</surname><given-names>G.</given-names></name><name><surname>Ponti</surname><given-names>A.</given-names></name><name><surname>Malila</surname><given-names>N.</given-names></name><name><surname>Arbyn</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <source><italic>Cancer Screening in the European Union Report on the Implementation of the Council Recommendation on Cancer Screening</italic>.</source>
<publisher-loc>First Report. Available at</publisher-loc>: <ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/health/ph_determinants/genetics/documents/cancer_screening.pdf"/>
<comment>(accessed June 20, 2013)</comment></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilschut</surname><given-names>J. A.</given-names></name><name><surname>Hol</surname><given-names>L.</given-names></name><name><surname>Dekker</surname><given-names>E.</given-names></name><name><surname>Jansen</surname><given-names>J. B.</given-names></name><name><surname>Van Leerdam</surname><given-names>M. E.</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Cost-effectiveness analysis of quantitative immunochemical test for colorectal cancer screening.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>141</volume>
<fpage>1648</fpage>&#x02013;<lpage>1655</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2011.07.020</pub-id><pub-id pub-id-type="pmid">21784045</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>B. C.</given-names></name><name><surname>Wong</surname><given-names>W. M.</given-names></name><name><surname>Cheung</surname><given-names>K. I.</given-names></name><name><surname>Tong</surname><given-names>T. S.</given-names></name><name><surname>Rozen</surname><given-names>P.</given-names></name><name><surname>Young</surname><given-names>G. P.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.</article-title>
<source><italic>Aliment. Pharmacol. Ther.</italic></source>
<volume>18</volume>
<fpage>941</fpage>&#x02013;<lpage>946</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01783.x</pub-id><pub-id pub-id-type="pmid">14616158</pub-id></mixed-citation></ref></ref-list></back></article>